TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Prescient Therapeutics Limited ( (AU:PTX) ).
Prescient Therapeutics Limited announced a change in the director’s interest, with Director James Campbell acquiring 750,000 fully paid ordinary shares through participation in a Share Purchase Plan. This acquisition increases his indirect holdings via Fusion Biosciences Pty Ltd, reflecting a significant vote of confidence in the company’s strategic direction and potential growth prospects.
More about Prescient Therapeutics Limited
Prescient Therapeutics Limited operates in the biotechnology industry, focusing on the development of targeted therapies for cancer treatment. The company leverages its expertise in oncology to advance innovative therapeutic solutions aimed at improving patient outcomes.
Average Trading Volume: 1,289,921
Technical Sentiment Signal: Sell
Current Market Cap: A$40.06M
For an in-depth examination of PTX stock, go to TipRanks’ Overview page.